The new financing was led by Venrock Healthcare Capital Partners with participation from other new and existing investors.

NEW YORK – Ohio State University researchers are using urine samples to understand bladder cancer patients' tumor microenvironments in several ongoing clinical trials, and they're confident the method ...

NEW YORK – The US Food and Drug Administration on Tuesday approved GSK's Wellcovorin (leucovorin calcium) as a treatment for adult and pediatric patients with cerebral folate deficiency who harbor ...

NEW YORK – Lyell Immunopharma has raised the second half of its planned $100 million private placement it launched last year, the company said Monday. The initial purchase agreement in July 2025 ...

The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

After a data monitoring committee saw increased risk of secondary blood cancers in the SYPHONY-1 trial, the firm will stop selling the drug for follicular lymphoma and sarcoma.

The House of Lords science and technology committee seeks answers to questions regarding the implementation of treatments like CAR T-cell and gene therapies.

While the US Food and Drug Administration touts new regulatory flexibility for rare disease drugs, recent rejections of ...

The company plans to combine the CAR designs with its in-house delivery platform to advance its in vivo CAR-M therapies toward clinical studies.

Metabolon helped Kite study the link between metabolic signatures and the severity of neurological evens in samples from ...